Mt. Arlington, N.J., Sept 16, 2014 (BUSINESS WIRE) — PDS, a leading global provider of intuitive data management software and solutions for life sciences research, announces that a top 5 pharma company has used TranSEND™ to successfully submit multiple SEND datasets derived from different data sources to the Food and Drug Administration (FDA).
“TranSEND is based on an intelligent software engine that automates and accelerates the SEND translation process,” said Sayed Badrawi, CEO of PDS. “The sophistication of our software engineering is a direct result of our deep understanding of preclinical data and the unique complexities that it entails. Our client’s submission success is a solid validation of our SEND solution.”
Developed by a team of expert programmers and scientists, TranSEND™ is a complete, platform-agnostic, Web-based software solution for aggregating and integrating data from multiple laboratory information management systems (LIMS) into a single set of harmonized SEND-compliant datasets for FDA submission.
With offices on three continents and clients spanning North and South America, Europe and Asia, PDS software is used by most of the world’s top 10 pharma companies. PDS is also the industry’s first provider to make an FDA-validated, preclinical research SEND dataset publicly available free of charge and qualification.
For more than 30 years, PDS has provided intuitive data management software and solutions for life sciences research and development programs worldwide. Most of the world’s top 10 pharma companies rely on PDS software, as do industry-leading CROs, chemical companies, universities and regulatory agencies. The PDS software lineup is centered on Ascentos™, your integrated preclinical software solution, which is purpose-built to support toxicology, clinical pathology, reproductive toxicology and pathology. PDS also offers TranSEND™, your complete FDA submission management solution, as well as powerful bioinformatics analysis and other services. Learn more at pdslifesciences.com.